Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 2
---
2025 |

<div align='center'>Up to[___] Shares of Common Stock

Pre-Funded Warrants to Purchase up to[___] Shares of Common Stock

Warrants to Purchase up to[___] Shares of Common Stock

Placement Agent Warrants to Purchase up to[___] Shares of Common Stock

Up to[___] Shares of Common Stock Issuable Upon Exercise of

Pre-Funded Warrants, Warrants and Placement Agent Warrants</div>

We are offering up to [___] shares (the “Shares”) of our common stock, par value $0.007 per share (the “Common Stock”), together with warrants to purchase up to [___] shares of Common Stock, which we refer to as the “April 2025 Warrants,” (such number of shares of Common Stock issuable upon exercise of the April 2025 Warrants equal to 150% of the number of Shares) pursuant to this prospectus. The assumed combined public offering price for each share of Common Stock and accompanying April 2025 Warrant to purchase one and one-half share of Common Stock is $[___], which is equal to the last reported sale price of our Common Stock on the Nasdaq Capital Market (“Nasdaq” or the “Nasdaq Capital Market”) on [___], 2025. Each share of our Common Stock is being sold together with one April 2025 Warrant to purchase one and one-half share of Common Stock. The April 2025 Warrants will have an exercise price of $[___] per share (115% of the combined public offering price per share of Common Stock and accompanying April 2025 Warrant) and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the April 2025 Warrants (“Warrant Stockholder Approval”), provided however, if the Pricing Conditions (as defined below) are met, the April 2025 Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The April 2025 Warrants will expire on the five-year anniversary of the Initial Exercise Date. As used herein, “Pricing Conditions” means that Warrant Stockholder Approval is not required under the Nasdaq rules because the offering is a discounted offering where the pricing and discount (including attributing a value of $0.125 for the April 2025 Warrants) meet the pricing requirements under the Nasdaq rules.

We are also offering to those purchasers, if any, whose